Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

Published:2019-06-28 Issue:20 Volume:125 Page:3603-3614
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Feun Lynn G.¹²^ORCID,Li Ying‐Ying²,Wu Chunjing³,Wangpaichitr Medhi⁴,Jones Patricia D.¹²,Richman Stephen P.¹²,Madrazo Beatrice⁵,Kwon Deukwoo⁶,Garcia‐Buitrago Monica⁷,Martin Paul²,Hosein Peter J.²,Savaraj Niramol²³

Affiliation:

1. Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida

2. Department of Medicine University of Miami Miller School of Medicine Miami Florida

3. Division of Hematology and Oncology Miami Veterans Affairs Healthcare System Miami Florida

4. Department of Surgery University of Miami Miller School of Medicine Miami Florida

5. Department of Radiology University of Miami Miller School of Medicine Miami Florida

6. Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida

7. Department of Pathology University of Miami Miller School of Medicine Miami Florida

Funder

Merck

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32339

Reference24 articles.

1. Focus on hepatocellular carcinoma

2. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030